OCTA in Evaluating Patients With AMD

Karl Csaky, MD, Ph.D., Chief Executive and Medical Officer of the Retina Foundation in Dallas, Texas, USA, defines the role of OCTA in evaluating age-related macular degeneration (AMD) with subclinical CNV, helps participants understand how to assess OCTA images and explores using OCTA in determining anti-VEGF treatment of neovascular AMD patients. Dr. Csaky is a frequent lecturer, author, experienced board-certified ophthalmologist, and leader in ophthalmic drug research and development, patient care, and the treatment of AMD.